Amgen Inc. (AMGN)

Total return at 5 years: -2.6%/year = -5.8% appreciation + 3.3% dividend. The target price ($309) is ex-dividend; the $60 in dividends collected over 5 years are added separately.

The methods disagree: one places the value today above the price ($418) and the other below.

Today — expensive, no margin of safety: at $418 trades ~38.9% above its value discounted to today (~$301); the expected return does not even reach the risk-free rate (4.5%).

At 5 years — Sobrevalorado: the expected total return is negative — the price already discounts a demanding scenario that, if not met, results in a loss.

The bridge: the return at 5 years falls below the risk-free rate (4.5%) — which is why there is not even a discount to today's value. To require a 15% annual return, it would need to be bought at ~$193.

Educational / informational. Does not constitute investment advice.

The inverse approach: instead of projecting growth to obtain the value, the market price ($418) is taken as given and it solves for what annual owner-earnings growth would need to hold for 5 years for the present value —at the method's rate (4.5%, no-growth terminal)— to equal that price. It is the disconfirmation test: the expectations the price already pays for, contrasted against the method's projection.

The market discounts less growth (3.5%/year) than we project (9.0%/year) → if the base case holds, there is margin: perception is more pessimistic than the estimated reality.

That growth implies ~$10.4 bn of owner earnings in year 5 (vs ~$13.5 bn of our base case). It recalculates if the DCF assumptions are edited.

Year-by-year projection of the selected scenario. From each year, two versions of the flow are derived: growth FCF (operating flow − total capex, the cash surplus) and maintenance FCF (the owner earnings: what the business yields if it only sustains its capacity). The flow is returned almost in full (dividend + buyback) or redeployed into the operation, so that EV stays roughly flat and multiples compress because the metric grows, not because of cash accumulation. The valuation is done on NOPAT (EV/NOPAT). In edit mode, revenue, margins, capex, and exit multiples can be adjusted.

Re-based to the TTM of 30-Jun-2026 (revenue $38.095bn, +9.1% YoY). The beaten-path flag (TTM +9.1% versus a modeled year 1 of +2.1%) is resolved by declaring, not by raising the band: year 1 remains anchored to the company's current guidance (§5 R1 prior) — now that of the 8-K of 4-Aug-2026 (Q2'26 results, Item 2.02), which supersedes the guidance of 30-Apr-2026 cited in the previous version. The company raised FY2026 guidance to revenue of $38.2-39.4bn (midpoint $38.8bn, up from $37.1-38.5bn) and GAAP earnings per share of $15.80-17.08 (from $15.62-17.10), with capex guided at ~$2.6bn (which already matched the model). Recalculating year 1 against the updated guidance and the new TTM ($38.095bn), implied growth is +1.85% — practically identical to the +2.1% the mechanical rebase carried —, because much of the trailing TTM strength (+9.1%) is already embedded in the higher base, and the guidance itself implies a deceleration in H2'26 (H1'26 actual $18.672bn +7.8% YoY; H2'26 implied by guidance ~$20.128bn, only +3.6% YoY) on tougher comps and the still-active erosion of the mature franchise. The Q2'26 breakdown confirms the trough-and-recovery thesis already declared, with a favorable nuance: the eroding block improves its rate of decline (ENBREL went from −37% in Q1'26 to just −4% in Q2'26, already benefiting from favorable sales-deduction adjustments that offset the Medicare price cut; Prolia −32% and XGEVA −34%, similar to Q1) and its weight in the mix falls from ~24.6% to ~16.8% of revenue year over year — exactly the mechanism by which the consolidated figure recovers without anything improving structurally. Year 1's anchors are set to the extremes and the midpoint of the updated guidance rather than to the mechanics of preserving the old rate: Base $38.80bn / net margin 23.09% (mid GAAP EPS $16.44 × 545M shares); Bear $38.20bn / 22.54% (floor EPS $15.80); Bull $39.40bn / 23.63% (ceiling EPS $17.08). The growth rates for years 2-5 (Base +4.0/+5.5/+6.0/+6.0%; Bear +1.0/+1.5/+2.0/+2.0%; Bull +6.5/+8.0/+8.0/+7.5%) are preserved unchanged: the erosion-recovery mix that underpins them was not altered by this quarter. The previous normalization of TTM GAAP earnings (a $400M residual of the Otezla impairment net of a $243M gain on debt extinguishment) is now obsolete: the 8-K of 4-Aug-2026 itself confirms that the Otezla intangible impairment charge (US$800M in total) fell entirely within the six months ended 30-Jun-2025, outside the current TTM window (Jul-2025 to Jun-2026) — the twelve-month GAAP figure ($8.743bn, a 22.95% margin) no longer requires that adjustment and is used directly as year 0. Separate note (it does not trigger an adjustment): the company authorized buybacks of up to $3.0bn for 2026 (against $0 in FY2025/FY2023), but under a hard rule of the method (§6: the buyback rate is anchored to sustained revealed behavior, never to a ceiling authorization) no `sharesPath` is modeled until actual execution is observed — it is left under watch for the next update.

Today's elevated multiple is the price of growth: if the business grows, the entry point cheapens on its own going forward (the metric grows while EV stays roughly flat). The exit multiple at 3 years is higher than the terminal at 5 years —at 3 years there is more growth still ahead—, so the value curve shows whether value creation is concentrated in the early or the later years. The required return is applied to the base scenario.

They are valued separately, with their own rationale, and are not incorporated into the base or the verdict (they are excess return). When assigning them value — in Editmode —, the total with optionalities updates live, without moving the base.

The verdict, the base CAGR, and the margin of safety are always calculated on the base; optionalities do not alter them (with optionalities at $0 they do not move).

Each card fixes a required annual return and answers: if the business is worth $309 in 5 years, what is the maximum that can be paid today to obtain that return? Since it now trades at $418, the margin of safety is how much cheaper the market is than that maximum. The three thresholds: 4% covers inflation (the floor), 10% is the long-term average return, and 15% is the level of a great investment.

With a target price of $309 in 5 years plus $60 of dividends collected (the dividend adds to the return, not to the price) and a required return of 4.5% annually, the maximum to pay today is $301. Against the current market price ($418), the margin of safety is -38.9% (trades above the maximum → a premium is paid) and the total return at that price would be -2.6% annually.

• Multiple vs. the band. EV/NOPAT ~28× on the normalized result — against the pharma band (14-22×), neither at the floor of a severe patent cliff nor at the ceiling of a franchise without erosion.
• No cycle trough or forced selling. There is no visible cyclical bottom or forced sale.
• Margin of safety. 5-year base case $309 vs. price $418 → -3%/year with dividend: Overvalued. A thin margin, not a bargain.

Each margin over sales, year by year: historical (solid line) → projection (dotted).

• ✓ ROIC exceeds the cost of capital (~10%)
• ✓ High incremental ROIC (compounding)
• ✓ CFROIC backs up the ROIC (110%, cash vs. accruals)
• ✕ Healthy balance sheet (low corporate debt)
• ✓ Durable competitive moat (multiple advantages)

• ROIC vs. the 10% bar. ROIC ~17.3% (normalized) — solid above the 10% bar. CFROIC (~19.4%) confirms that the return is backed by real cash.
• Cash quality. Trailing-twelve-month operating cash flow ($10.8bn) covers capex ($2.2bn) and a good portion of the dividend. The Otezla impairment and the gain on debt extinguishment are non-cash/non-recurring items, already disclosed.
• Post-M&A balance sheet. Net debt ~$45.3bn (from Horizon, Oct 2023), with staggered maturities and investment-grade across all three agencies; leverage ~2.9× EBITDA, coverage ~4.1×. The company already retired $6.0bn in 2025—the trend is deleveraging.

Annual levels from the official filing (10-K); the % over each bar is the year-over-year (YoY) growth vs the prior year.

Amgen's engine is volume × price/mix over a diversified portfolio of biologics: consolidated product sales growth (+10% in 2025) comes from volume +13% (United States +13%, rest of the world +14%), partially offset by a -3% decline in net price/mix. Beneath the consolidated figure there are large divergences by product: Repatha (PCSK9) is growing strongly after the August-2025 indication expansion, and TEZSPIRE/UPLIZNA/IMDELLTRA are scaling as recent launches, while Prolia/XGEVA (RANKL patents expired Feb/Nov-2025, with accelerated erosion guided for 2026) and ENBREL (Medicare pricing from Jan-2026, plus the Colorado state payment cap from 2027) face structural erosion — ENBREL sales already fell 33% in 2025 (net price -36%). Capital expenditure is accelerating (guidance of ~$2.6bn for 2026, after $1.9bn in 2025) to expand biologics manufacturing (Holly Springs, New Albany, Puerto Rico), which also underpins the Section 232 tariff relief obtained in December-2025.

The % are the annual (year-over-year) growth: each year —historical and projected— vs the prior one; the TTM (trailing 12m) vs the TTM of a year ago, to avoid overlapping windows. The historicals are exact figures from the official filings; the projected years come from the year-by-year model (the intermediate years without their own series are interpolated between the anchors). The projected columns (+1y…+5y) are 12-month windows counted from the TTM close (30-jun-2026): the projection starts from the most recently reported data, not the fiscal year. The projected base is realistic and unbiased — the risk discount is applied at the end, via the required return. The rationale for each metric is in the (i).

• Real, not nominal. The +10% in 2025 is volume (+13%) net of price (-3%) — real unit growth, not just pricing. FY2024 (+18.6%) was inflated by the full-year effect of the Horizon acquisition.
• Growth engine. Repatha (indication expansion), TEZSPIRE, UPLIZNA, and IMDELLTRA (recent launches) offset the erosion of Prolia/XGEVA/ENBREL/Otezla. The pipeline (MariTide) is the long-term optionality.
• Deceleration and erosion. The model starts from the company's 2026 guidance (+2.1%) and recovers toward +6.0% by year 5 as the eroding block loses weight in the mix — not constant growth, and not a linear deceleration.

• Relevant in 10 years (recurrence). Amgen's biologics treat serious chronic diseases (osteoporosis, cancer, cardiometabolic/respiratory diseases) — recurring consumption with significant unmet medical need. High recurrence.
• Pricing power. Eroding: net price/mix fell -3% in 2025 (offset by volume +13%); Medicare pricing already reached ENBREL and Otezla, and now state price controls add (Colorado declared ENBREL 'unaffordable').
• Moat and its direction. Wide moat (patents + biologic manufacturing scale) but actively eroding, company-guided: Prolia/XGEVA biosimilars already competing since Feb/Nov 2025, with 'accelerated sales erosion' expected for 2026.
• Portfolio diversification. Without extreme single-product concentration (unlike other oncology pharmaceutical companies): Prolia/XGEVA, Repatha, Otezla, ENBREL, TEZSPIRE, KYPROLIS spread the risk.

Not all debt is equal: only the structural needs refinancing; the rest is operational (self-liquidating).

Structural debt is what is exposed to the contraction phase of the cycle; operational debt (leases, matched funding) self-liquidates with the business.

• ✓Leverage (net debt / EBITDA)Net cash $0 bn
• !Interest coverage (EBIT / interest)4.1x
• –Liquidity (current ratio)no data
• ✓Cash quality (CFROIC vs ROIC)CFROIC backs 110% of ROIC
• ✓Value creation (ROIC − 10% bar)+7pp
• ✓Malinvestment test (capex vs incremental ROIC)Capex/D&A 0.5x — no over-investment
• !Float / working capitalConsumes cash $2.6 bn (positive WC)
• ✓Dilution (SBC % of revenue + shares)SBC 1.3% of revenue

A traffic-light interpreted by the method (not generic): float (negative WC) adds up, capex is judged by incremental ROIC (malinvestment test), and a lender is not subjected to corporate solvency. The (i) shows the derivation of each number.

• Leverage. Net debt ~$45.3bn from Horizon acquisition (Oct 2023); ~2.9× EBITDA, interest coverage ~4.1×, investment-grade across all three agencies (S&P BBB+, Moody's Baa1, Fitch BBB+). Manageable, with active deleveraging and staggered maturities without concentration wall.
• Cash generation. Twelve-month operating cash flow $10.8bn; capex $2.2bn (FY26 guidance ~$2.6bn to expand manufacturing), plus declared purchase obligations of ~$6.9bn (mostly R&D and short-term capex). Stock-based compensation is small (~1.3% of revenue)—no dilution trap.
• Dividend sustainability. Dividend covered by cash flow; a 6% increase declared in December-2025, the second consecutive 6% increase (after the 2024 one). Cash priority: debt first, then the dividend, buybacks paused.

How cash comes in and how it is deployed. In green, the business's own cash (the owner-FCF it generates and reinvests); in gray, the float and credit — customer and funding money, which is not the shareholder's.

Within recurring cash flow (excluding debt repayment), capital is split between capital expenditure (~28%, including the manufacturing expansion) and the dividend (~72%, with a 6% increase declared in December-2025, the second consecutive one of that size). Buybacks are paused. Beyond that, 2025 was a year of active deleveraging: $6.0bn of debt retired (repayments plus bond buybacks), funded in part with existing cash — the temporary priority is reducing the debt from the Horizon acquisition before resuming buybacks.

Who owns the shares — the alignment and whether there is a controlling shareholder.

• Skin in the game. Insiders <1% as a group (standard proxy disclosure); no controlling shareholder. BlackRock (7.6%) and State Street (5.5%) are the only disclosed holders above 5%.
• Capital allocation. 2025 priority: debt repayment ($6.0bn) over buyback (paused, $0). Dividend with 6% increase announced December 2025—the second consecutive 6% raise, following 2024. Deleveraging discipline post-Horizon acquisition.
• Integrity / normalization. The Otezla impairment ($1.2bn, tied to Medicare price-setting), the decision not to withdraw TAVNEOS despite the FDA request, and the IRS dispute (disclosed gross exposure of up to ~$10.7bn) are all disclosed transparently in the 10-K.

• There is no clear source of discount: Amgen is not at a cyclical bottom or under a forced sale.
• The trailing-twelve-month GAAP figure looks expensive due to the residual of the Otezla impairment still weighing on that window ($400M of the $1,200M total in 2025); on the normalized result the entry multiple is ~28×, still not a bargain.
• The market is paying for optimism on the pipeline (MariTide, Repatha, TEZSPIRE, UPLIZNA, IMDELLTRA) that has to offset the Prolia/XGEVA biosimilar erosion and the state-level price controls now adding to the federal ones on ENBREL, both already under way — a bet on execution, not a discount from mistaken perception.

Without identifiable missing buyers or motivated sellers: the price already reflects a reasonable balance between the pipeline and the erosion of the oldest franchise. It is a business of real quality at a full price, not a bargain with an identifiable discount catalyst.

The annual return (CAGR at 5 years) in each scenario, with the total period return below — the margin of safety made visual: upside range wide, downside range narrow.

Even in the bear scenario, the return holds at -13%/year (-50% total): the margin of safety protects the downside. The bull (+4%/year, +19% total) exceeds it comfortably — a favorable asymmetry, with a narrow downside range and a wide upside range.

• Biosimilar erosion (Prolia/XGEVA). Central disconfirmer: RANKL patents expired Feb/Nov 2025, multiple biosimilars are already competing, and the company guides accelerated sales erosion for 2026 in both products.
• Medicare price-setting. ENBREL (Jan 2026) and Otezla (Jan 2027) already have CMS pricing; state price controls now add—Colorado declared ENBREL unaffordable (payment cap from 2027) and Washington selected it for review—and up to 100 drugs could be added to the federal list by 2031.
• IRS litigation (Puerto Rico). Dispute over 2010-2018 profit allocation with gross exposure up to ~$10.7bn against net equity of $8.66bn at end 2025; ruling not expected before H2 2026, and the IRS is already auditing later years with similar issues.
• Debt + channel concentration. Net debt ~$45bn from Horizon acquisition; three wholesalers concentrate 77% of gross revenues and the six largest US integrated plans/pharmacy benefit managers control ~89% of prescriptions—two points of negotiation leverage concentrated in the value chain.

Each thinker's analytical framework applied to our data.

• Buffett / Graham Quality + margin of safety

  Fails the quality gate: wide moat, eroding.

• Peter Lynch Growth at a reasonable price (GARP)

  A fast grower growing 9% at a multiple/growth of 3.1 → expensive for its growth.

• Joel Greenblatt Cheap and high-return (Magic Formula)

  Earnings yield 5% (EBIT/EV) + ROIC 17% → falls outside the Magic Formula.

• Howard Marks Perception vs reality + cycle

  The price discounts 3% vs our 9%: perception is more pessimistic than reality, with an identified source of the discount.

• Seth Klarman Capital protection (bear scenario)

  Bear-scenario floor -17%/yr over 5y (material loss) → risk of permanent capital loss.

• Pat Dorsey Moat strength (Five Rules)

  A wide moat, eroding; sources: intangibles, efficient scale, switching costs → partially passes the Five Rules.

• Aswath Damodaran Expectations implied by the price

  Justifying the price requires discounting 3%, within what we project (9%) — the story squares with the numbers.